Onconova Therapeutics Inc Share Price Nasdaq
Equities
US68232V1089
Biotechnology & Medical Research
Sales 2024 * | 210K 17.54M | Sales 2025 * | 300K 25.05M | Capitalization | 16.45M 1.37B |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.92B | Net income 2025 * | -28M -2.34B | EV / Sales 2024 * | 78.3 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 54.8 x |
P/E ratio 2024 * |
-0.75
x | P/E ratio 2025 * |
-0.78
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.39% |
Latest transcript on Onconova Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 19/15/19 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 01/13/01 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 24/23/24 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 01/15/01 |
Jack Stover
BRD | Director/Board Member | 69 | 23/16/23 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 01/20/01 |
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |